Kamel Hacene
Overview
Explore the profile of Kamel Hacene including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pichon M, Brun G, Hacene K, Basuyau J, Riedinger J, Eche N, et al.
Clin Chem Lab Med
. 2009 Jun;
47(8):985-92.
PMID: 19548847
Background: Quality control results for serum MUC-1/CA 15-3 assays have always shown large discrepancies. Methods: This multicentre study of 15 methods (labelled M1-M15) measured coded sera from 35 patients with...
2.
Triebel F, Hacene K, Pichon M
Cancer Lett
. 2005 Jun;
235(1):147-53.
PMID: 15946792
In contrast to the long-held belief that breast cancer is a weakly immunogenic tumor, accumulating evidence indicates an immune infiltrate is an invariable finding in breast cancers, raising hopes that...
3.
Bethune-Volters A, Labroquere M, Guepratte S, Hacene K, Neumann R, Carney W, et al.
Anticancer Res
. 2004 May;
24(2C):1083-9.
PMID: 15154627
Background: To evaluate longitudinal variations of serum HER-2/neu extracellular domain (sHER-2) in metastatic breast cancer patients receiving combined trastuzumab treatment. Patients And Methods: Thirty-three patients were monitored by serial sHER-2...
4.
Pichon M, Hacene K, Guepratte S, Neumann R
Clin Lab
. 2004 Apr;
50(3-4):163-70.
PMID: 15074470
We studied the serum HER-2 extracellular domain (sHER-2) before the first metastases in 128/701 breast cancer patients diagnosed and followed-up in our institution who developed metastases as the first relapse....
5.
Lerebours F, Bertheau P, Bieche I, Plassa L, Champeme M, Hacene K, et al.
Clin Cancer Res
. 2003 Oct;
9(11):4184-9.
PMID: 14519644
Purpose: The prognosis of inflammatory breast cancer (IBC) remains poor despite the use of multimodality treatments, with a 10-year survival rate of not >30%. Clinicopathological and biological predictors of outcome...
6.
Spyratos F, Bouchet C, Ferrero-Pous M, Tubiana-Hulin M, Hacene K
J Natl Cancer Inst
. 2003 Sep;
95(18):1417-8; author reply 1418.
PMID: 13130118
No abstract available.
7.
Meduri G, Charnaux N, Spyratos F, Hacene K, Loosfelt H, Milgrom E
Cancer
. 2003 Mar;
97(7):1810-6.
PMID: 12655539
Background: It has been established that pregnancy protects against breast carcinoma, and animal models have shown that human chorionic gonadotropin (hCG) mimics this effect by inhibiting the initiation and progression...
8.
Lerebours F, Bertheau P, Bieche I, Driouch K, de The H, Hacene K, et al.
Int J Cancer
. 2002 Nov;
102(6):618-22.
PMID: 12448004
Inflammatory breast cancer (IBC) is a rare but particularly aggressive form of primary breast cancer. In contrast to noninflammatory breast cancer (non IBC), the molecular alterations underlying IBC are poorly...
9.
Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, et al.
Cancer
. 2002 May;
94(8):2151-9.
PMID: 12001111
Background: Cell proliferation is a major determinant of the biologic behavior of breast carcinoma. MIB-1 monoclonal antibody is a promising tool for determining cell proliferation on routine histologic material. The...